Loading…
← CockpitCompetitor Analysis › INDP Indaptus Therapeutics, Inc.Open in the cockpit ↗

Indaptus Therapeutics, Inc.INDPCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum leader 100
Mkt cap
$505M
US dollars, full cap
Free float
5%
of shares outstanding
$/day
$753,592
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 9.9%
Hurdle
n/a
no reverse DCF
Next earnings
113 days
11 Mar 2027
Close · USD$3.29
1D-0.9%
1W+2.5%
1M+11.2%
3M+250.0%
6M+147.4%
YTD+13.1%
1Y+31.1%
ATR %11.0%
Beta1.70
52w lowhigh44.8% off high

What Indaptus Therapeutics does

Employees: 5

Indaptus Therapeutics at a glance

Size Indaptus Therapeutics (INDP) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $505M, the 2663rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.29 on 18 Nov 2026.

Performance Over six months the shares gained 147.4%, against -20.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 19 in its peer set.

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

10020030040021 May 202621 Aug 202618 Nov 2026INDP 267Peer median 81
Six months, rebased to 100: Indaptus Therapeutics against the median of its 20 peers (local-currency closes).

Indaptus Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit$0$0-$735-$1,284-$1,781
EBITDA-$13.3M-$19.8M-$15.4M-$16.4M-$14.9M
Net income-$13.5M-$20.8M-$15.0M-$15.4M-$14.3M
Free cash flow-$14.0M-$14.8M-$12.3M-$13.4M-$13.1M
Capital expenditure$0$0$0$0$0
Total debt$0$0$84,164$175,053$80,494

Quarterly statements and history in the cockpit →

Indaptus Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%GUJTHEM603207EGTXGYRE603676600222TKNO600513003090AARTIDRUGS1666301277003020SUPRIYAINDP6-month return →1-month return →
Up and to the right = strong over both horizons. Indaptus Therapeutics is the large dot.

Indaptus Therapeutics competitors and peer comparison

How Indaptus Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Indaptus Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureINDPPeer medianRank in peer set
1-month return+11.2%-7.0%3rd highest of 20
6-month return+147.4%-20.4%highest of 19
Distance from 52-week high-44.8%-39.7%8th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%27.2×n/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%4.8×-5.4%+7.6%
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%71.0×n/an/a
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%4.0×n/an/a
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%2.3×-6.1%+9.6%
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%2.5×16.7%+4.4%
Alpha Teknova TKNOUnited States$496M+113%+15%-32%11.0×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%1.8×n/an/a
Daewoong 003090.KSSouth Korea$495M-28%+6%11%0.9×n/an/a
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%1.8×22.1%+3.5%
Beijing Science Sun Pharmaceutical 300485.SZChina$517M-29%-11%-8%5.6×n/an/a
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%16.2×49.3%-1.5%
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%5.5×28.2%+15.8%
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%0.7×2.4%+5.0%
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a

Questions

Which companies are Indaptus Therapeutics's closest peers?
The cockpit's peer set: Gujarat Themis Biosyn (GUJTHEM.NS), Shanghai Xiao Fang Pharmaceutical (603207.SS), Egetis Therapeutics (EGTX.ST), Gyre Therapeutics (GYRE), Xizang Weixinkang Pharmaceutical (603676.SS), Henan Taloph Pharmaceutical Stock (600222.SS), Alpha Teknova (TKNO), Jiangsu Lianhuan Pharmaceutical (600513.SS).
How has Indaptus Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +147.4% against -20.4% for the median peer; over one year +31.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.